Previous Close | 3.0900 |
Open | 3.1100 |
Bid | 3.3100 x 1100 |
Ask | 3.5800 x 800 |
Day's Range | 2.9463 - 3.1100 |
52 Week Range | 0.8600 - 6.9800 |
Volume | |
Avg. Volume | 346,536 |
Market Cap | 196.772M |
Beta (5Y Monthly) | 2.69 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.9600 |
Earnings Date | May 08, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.25 |
Advancements in Genetic Medicine Platforms Highlighted Amid Financial Review
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -29.27% and 5.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia - Development of breakthrough immune-quiet DNA for hemophilia A program continues - Cash balance of $264.4 million expected to fund operations into 2H 2027 CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent